Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetics-guided dosing versus usual dosing in psychiatry
NL-OMON61026Phase 4Recruiting
- Sponsor
- Parnassia Groep
- Start
- Apr 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of aripiprazole, sertraline, escitalopram and risperidone in major depressive disorder (MDD), bipolar disorder (BD), anxiety disorder and 2 more (2 arms), sponsored by Parnassia Groep. Primary endpoint: Patient recovery. Started Apr 2026; status: recruiting.
02
Drugs
aripiprazolesertralineescitalopramrisperidone
03
Conditions
major depressive disorder (MDD)bipolar disorder (BD)anxiety disorderschizophreniaschizoaffective disorder
Beyond the preview
Go deeper on NL-OMON61026.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61026.